1-(3-(phenyl)propyl)piperidin-4-amine | 54729-43-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-(phenyl)propyl)piperidin-4-amine
• 英文别名: 4-amino-1-(3-phenylpropyl)piperidine；1-(3-Phenylpropyl)piperidin-4-amine
• CAS: 54729-43-0
• 化学式: C₁₄H₂₂N₂
• mdl: MFCD09811503
• 分子量: 218.342
• InChiKey: FTWWEFSFFIMPQU-UHFFFAOYSA-N

物化性质

• 沸点：
  337.7±42.0 °C(Predicted)
• 密度：
  0.993±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4-二氯喹唑啉 、 1-(3-(phenyl)propyl)piperidin-4-amine 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Identification of novel quinazoline derivatives as potent antiplasmodial agents

  摘要：

  Despite the recent reductions in the global burden of malaria, this disease remains a devastating cause of death in tropical and subtropical regions. As there is no broadly effective vaccine for malaria, prevention and treatment still rely on chemotherapy. Unfortunately, emerging resistance to the gold standard artemisinin combination therapies means that new drugs with novel modes of action are urgently needed. In this context, Plasmodium histone modifying enzymes have emerged as potential drug targets, prompting us to develop and optimize compounds directed against such epigenetic targets. A panel of 51 compounds designed to target different epigenetic enzymes were screened for activity against Plasmodium falciparum parasites. Based on in vitro activity against drug susceptible and drug-resistant P. falciparum lines, selectivity index criterion and favorable pharmacokinetic properties, four compounds, one HDAC inhibitor (1) and three DNMT inhibitors (37,43 and 45), were selected for preclinical studies in a mouse model of malaria. In vivo data showed that 37, 43 and 45 exhibited oral efficacy in the mouse model of Plasmodium berghei infection. These compounds represent promising starting points for the development of novel antimalarial drugs. Crown Copyright (C) 2018 Published by Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.10.041
• 作为产物：
  描述：

  1-(3-phenylpropyl)-4-aminopyridinium bromide 在 sodium tetrahydroborate 作用下， 以 甲醇 、 异丙醇 为溶剂， 反应 2.0h， 以70.8%的产率得到1-(3-(phenyl)propyl)piperidin-4-amine
  参考文献：
  名称：

  低密度脂蛋白受体上调剂 N-[1-(3-Phenylpropane-1-yl)piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboamide 的实用合成

  摘要：

  一种更短更实用的制备 N-[1-(3-phenylpropane-1-yl)piperidin-4-yl]-5-thia-1,8b-diazaacenaphthylene-4-carboxamide (4) 作为上调剂的方法已开发出 LDL 受体。1-(3-苯丙基)哌啶-4-胺 (7) 是通过用 3-苯丙基溴将 4-氨基吡啶 (5) 烷基化，然后在碱存在下在 2 -丙醇和甲醇。在上述还原中加入碱（1 equiv），例如 KOH 和 NaOMe，可减少 1-（3-苯基丙基）-N-[1-（3-苯基丙基）哌啶-4-基]哌啶- 4-胺 (8) 以提高 7 的产率。在 HOBt (0.2 equiv) 存在下使用 EDCI 将 5-thia-1,8b-diazaacenaphthylene-4-carboxy 酸 (1) 与伯胺 (7) 酰胺化) 以 94% 的收率提供 4。

  DOI：

  10.1021/op0101106

文献信息

• Fused imidazopyridine derivatives as antihyperlipidemic agents
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06235731B1

  公开（公告）日：2001-05-22

  A novel compound of the formula: wherein ring Q is an optionally substituted pyridine ring; One of R0, R1 and R2 is —Y0—Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group; Y0 is a bond or an optionally substituted bivalent hydrocarbon group; Z0 is a basic group which may be bonded via oxygen, nitrogen, —CO—, —CS—, —SO2N(R3)— (where R3 is hydrogen or an optionally substituted hydrocarbon group), or S(O)n (wherein n is to 0, 1 or 2); ......... is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.

  其中环Q是一个可选择取代的吡啶环； R0、R1和R2中的一个是—Y0—Z0，另外两个基团是氢、卤素、可选择取代的羟基、可能是可选择取代的碳氢基团或酰基； Y0是一个键或一个可选择取代的二价碳氢基团； Z0是一种碱性基团，可以通过氧、氮、—CO—、—CS—、—SO2N(R3)—（其中R3是氢或可选择取代的碳氢基团）或S(O)n（其中n为0、1或2）与之键合； .........是一种单键或双键，或其盐，具有出色的LDL受体上调、降低血脂、降低血糖和改善糖尿病并发症的活性。
• Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position
  作者：Thuy Nguyen、Yuji Sakasegawa、Katsumi Doh-ura、Mei-Lin Go

  DOI：10.1016/j.ejmech.2011.04.016

  日期：2011.7

  In this paper, we report the synthesis and cell-based anti-prion activity of quinacrine analogs derived by replacing the basic alkyl side chain of quinacrine with 4-(4-methylpiperazin-I-yl)phenyl, (1-benzylpiperidin-4-yl) and their structural variants. Several promising analogs were found that have a more favorable anti-prion profile than quinacrine in terms of potency and activity across different

  在本文中，我们报道了用4-（4-甲基哌嗪-1-基）苯基，（1-苄基哌啶-4- yl）及其结构变体。发现在不同different病毒感染的鼠细胞模型的效价和活性方面，一些有前途的类似物在抗病毒方面比奎纳克林更有利。它们还表现出对人类病毒蛋白片段的更高结合亲和力（hPrP 121–231）比奎纳克林高，并且在PAMPA-BBB分析中的渗透率在CNS渗透候选物范围内。当在过表达Pgp的细胞系上进行双向分析评估时，与奎纳克林相比，一种类似物对Pgp外排活性的敏感性较低。两者合计，结果表明连接到a啶，四氢ac啶和喹啉骨架上的取代9-氨基侧链的重要作用。该侧链的性质影响基于细胞的效能，PAMPA渗透性和对hPrP 121-231的结合亲和力。
• [EN] COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DE LA MUCOVISCIDOSE ET D'AUTRES MALADIES CHRONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2011050325A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one compound of Formula I, Formula II, or Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及一种药物组合物，包括一种上皮钠通道活性抑制剂与至少一种公式I、公式II或公式III的化合物结合。本发明还涉及其固体形式和制药配方，以及使用这种组合物治疗CFTR介导疾病，尤其是囊性纤维化的方法。
• 3-indolecarboxamides for control of circulatory diseases
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US04581355A1

  公开（公告）日：1986-04-08

  3-Indolecarboxamide compounds of the formula: ##STR1## inclusive of pharmaceutically acceptable acid addition salt and/or hydrate forms thereof, wherein R.sup.1 is hydrogen or C.sub.1-4 alkyl; each of R.sup.2 and R.sup.3 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, benzyloxy, C.sub.2-6 alkanoyloxy or hydroxy; R.sup.4 is hydrogen or C.sub.1-4 alkyl; R.sup.5 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy; R.sup.6 is hydrogen or C.sub.1-4 alkyl; X is oxygen, sulfur or direct bond; each of k and m is an integer of 1 to 3; and n is 1 or 2, are useful as drug for the prevention and treatment of various circulatory diseases.

  式为：##STR1## 包括其药学上可接受的酸加盐和/或水合物形式，其中R.sup.1是氢或C.sub.1-4烷基；R.sup.2和R.sup.3中的每一个是氢，卤素，C.sub.1-4烷基，C.sub.1-4烷氧基，苄氧基，C.sub.2-6烷酰氧基或羟基；R.sup.4是氢或C.sub.1-4烷基；R.sup.5是氢，卤素，C.sub.1-4烷基，C.sub.1-4烷氧基或羟基；R.sup.6是氢或C.sub.1-4烷基；X是氧，硫或直接键；k和m中的每一个是1至3的整数；n是1或2，可用于预防和治疗各种循环系统疾病的药物。
• Novel catechol derivatives
  申请人：Japan Tobacco Inc.

  公开号：EP0354568A2

  公开（公告）日：1990-02-14

  Catechol derivatives represented by the general formula: wherein each symbol is as defined in the specification and their pharmaceutically acceptable acid addition salts. Said derivatives are useful for the prevention or treatment of degenerative neurological diseases.

  由通式代表的儿茶酚衍生物： 其中各符号如说明书中所定义，以及它们的药学上可接受的酸加成盐。 上述衍生物可用于预防或治疗神经系统退行性疾病。